Gilead Sciences, Inc. GILD and partner Merck MRK announced positive data from two late-stage studies, ISLEND-1 and ISLEND-2, ...

Gilead and MSD will be filing the data from the Phase III trials of the once-weekly HIV pill to regulatory authorities.

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

A new antiretroviral target has been identified that suppresses HIV-1 replication and selectively kills HIV-1-infected cells. HIV-1 is the most common type of HIV. When HIV-1 leaves infected cells, ...

Since HIV’s discovery in the 1980s, scientists have come a long way in understanding the different steps required for its assembly and maturation. Researchers knew, for instance, that HIV wraps its ...

Excision BioTherapeutics has so far released positive safety data from the first 3 participants living with HIV-1, with no evidence of vector shedding in sexual organ tissue. A cure for HIV-1 becomes ...

Gilead Sciences, Inc. GILD has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy for treatment and ...

A study by chemists at the University of Chicago has uncovered a new key step in the process that HIV uses to replicate itself. The study, published Jan. 6 in Science Advances, used computer modeling ...

Researchers at Johns Hopkins Medicine, in collaboration with researchers at the National Institutes of Health, report that two new studies in mice with a humanized immune system and human cell lines ...

Scientists appear to have discovered a way to produce a true structure of the rare but naturally-occurring anti-HIV compound Lancilactone C from start to finish. The domino-like reaction enables the ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

University of Delaware professor Juan Perilla (right), is co-author of a new paper that reveals a previously unknown structural role for integrase, a key HIV protein, earlier in the virus' life cycle ...